Can AI Agents Help Get Therapies to Patients Faster?
Medable’s Pam Tenaerts explains how decentralized technologies and AI agents can cut clinical trial bottlenecks from days to hours.
Clinical trials generate enormous amounts of data—but the people running them can spend an extraordinary amount of time simply finding, connecting and making sense of that information.
Pam Tenaerts, Chief Medical Officer at Medable, says the opportunity for AI isn’t just to automate clinical research. It’s to remove the operational bottlenecks that slow trials down.
Medable is combining decentralized trial technologies—which allow more of the trial to come to participants and research sites—with AI agents designed to help clinical trial teams work across fragmented systems.
Consider the clinical trial monitor. Tenaerts says the average monitor may need to work across 13 different systems, repeatedly logging in and out, connecting information and preparing for site visits.
🤖 Medable’s approach uses AI agents—including specialized sub-agents coordinated by what Tenaerts describes as a “super agent”—to do much of that preparatory work.
The potential impact is substantial: reducing preparation for a site visit from days to hours.
But Tenaerts says the real objective isn’t simply efficiency.
“What we’re trying to do is eliminate that bottleneck, which eventually will mean better therapies to patients who need it.”
💡 Why it matters: Every unnecessary delay inside a clinical trial can ultimately become a delay in getting an effective therapy to patients. If AI can safely compress the administrative and operational work surrounding clinical research, its value won’t just be measured in hours saved—it could be measured in how quickly new treatments reach the people waiting for them.
▶️ Watch the HITshow conversation with Pam Tenaerts, Chief Medical Officer at Medable.
#HITshow #Medable #ClinicalTrials #ClinicalResearch #ArtificialIntelligence #AI #AIAgents #DecentralizedClinicalTrials #DigitalHealth #LifeSciences #HealthTech
